Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs

General Pharmacology

Volumn 30, Issue 1, 1998, Pages 137-142

  Natsukawa, Takashi ^a   Matsuzaki, Takushi ^a   Hayashi, Seiji ^a   Ukai, Yojiro ^a   Yoshikuni, Yoshiaki ^a   Kimura, Kiyoshi ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

NS 21; QTc interval; RCC 36; Terodiline; Torsade de pointes

Indexed keywords

2 CYCLOHEXYL 2 HYDROXY 2 PHENYLACETIC ACID 4 ETHYLAMINO 1,1 DIMETHYL 2 BUTYNYL ESTER; DRUG METABOLITE; TEMIVERINE; TERODILINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; ELECTROCARDIOGRAM; FEMALE; GUINEA PIG; HEART MUSCLE POTENTIAL; HEART VENTRICLE TACHYCARDIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

EID: 0031986271     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00025-6     Document Type: Article

References (27)

1. Andersson K. E. (1988) Current concepts in the treatment of disorders of micturition. Drugs 35, 477-494.
2. Benedict C. R. (1993) The QT interval and drug-associated torsades de pointes. Drug Invest. 5, 69-79.
3. Connolly M. J., Astridge P. S., White E. G., Morley C. A. and Cowan J. C. (1991) Torsades de pointes ventricular tachycardia and terodiline. Lancet 338, 344-345.
4. Day C. P., McComb J. M. and Campbell R. W. F. (1990) QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br. Heart J. 63, 342-344.
5. Freeman J. W., Mundy G. R., Beattie R. R. and Ryan C. (1969) Cardiac abnormalities in poisoning with tricyclic antidepressants. Br. Med. J. 2, 610-611.
6. Hamada K., Sasaki Y., Taniguchi N., Miyatsuka Y., Yamazaki C., Kimura Y., Ukai Y., Yoshikuni Y. and Kimura K. (1997) Anticholinergic and calcium antagonistic activity of NS-21 in the inhibition of rat urinary bladder contractions. Gen. Pharmac. 29:5, 771-778.
7. Hayashi S., Natsukawa T., Suma C., Ukai Y., Yoshikuni Y. and Kimura K. (1997) Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline. Naunyn-Schmiedeberg's Arch Pharmac. 355, 651-658.
8. Hussain R. M., Hartigan-Go K., Thomas S. H. L. and Ford G. A. (1996) Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br. J. Clin. Pharmac. 41, 73-75.
9. Husted S., Andersson K. E., Sommer L. and Østergaard J. R. (1980) Anticholinergic and calcium antagonistic effects of terodiline in rabbit urinary bladder. Acta Pharmac. Toxicol. (Copenh.) 46 (Suppl 1), 20-30.
10. Isenberg G. and Tamargo J. (1985) Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes. Eur. J. Pharmac. 108, 121-131.
11. Kimura Y., Fukui H., Hamada K., Ogasawara T., Yamazaki C., Ukai Y., Yoshikuni Y. and Kimura K. (1997) Effect of the anticholinergic drug with calcium antagonistic activity, (±)-4-diethylamino-1,1-dimethyl-but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate, on lower urinary tract function in decerebrated dogs. Arzneim. -Forsch. Drug Res. 47, 182-189.
12. MacConnell T. J. and Stanners A. J. (1991) Torsades de pointes complicating treatment with terfenadine. Br. Med. J. 302, 1469.
13. McLeod A. A., Thorogood S. and Barnett S. (1991) Torsades de pointes complicating treatment with terodiline. Br. Med. J. 302, 1469.
14. + channels in guinea pig ventricular myocytes. J. Cardiovasc. Pharmac. 26, 761-769.
15. Nguyen P. T., Scheinman M. M. and Seger J. (1986) Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation 74, 340-349.
16. Pressler M. L., Warner M. R., Rubart M., Rardon D. P. and Zipes D. P. (1995) In vivo and in vitro electrophysiologic effects of terodiline on dog myocardium. J. Cardiovasc. Ekctrophysiol. 6, 443-454.
17. Rawling D. A. and Fozzard H. A. (1979) Effects of imipramine on cellular electrophysiological properties of cardiac Purkinje fibers. J. Pharmac. Exp. Ther. 209, 371-375.
18. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ. Res. 76, 110-119.
19. Sanguinetti M. C. (1992) Modulation of potassium channels by antiarrhythmic and antihypertensive drugs. Hypertension 19, 228-236.
20. Stewart D. A., Taylor J., Ghosh S., Macphee G. J. A., Abdullah I., McLenachan J. M. and Stott D. J. (1992) Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur. J. Clin. Pharmac. 42, 577-580.
21. Stratmann H. G. and Kennedy H. L. (1987) Torsades de pointes associated with drugs and toxins: recognition and management. Am. Heart J. 113, 1470-1482.
22. Strauss H. C., Bigger J. T. Jr. and Hoffman B. F. (1970) Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ. Res. 26, 661-678.
23. Tan H. L., Hou C. J. Y., Lauer, M. R. and Sung R. J. (1995) Electrophysiological mechanisms of the long QT interval syndromes and torsade de pointes. Ann. Intern. Med. 122, 701-714.
24. Thomas S. H. L., Higham P. D., Hartigan-Go K., Kamali F., Wood P., Campbell R. W. F. and Ford G. A. (1995) Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br. Heart J. 74, 53-56.
25. + current activation in guinea pig ventricular myocytes. Circ. Res. 74, 687-699.
26. Winslow E., Campbell J. K. and Marshall R. J. (1986) Comparative electrophysiological effects of disopyramide and bepridil on rabbit atrial, papillary, and Purkinje tissue: modification by reduced extracellular potassium. J. Cardiovasc. Pharmac. 8, 1208-1216.
27. Zipes D. P. (1987) Proarrhythmic effects of antiarrhythmic drugs. Am. J. Cardiol. 59, 26E-31E.